ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 43 filers reported holding ONCOMED PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $51,000 | +75.9% | 24,200 | +95.2% | 0.00% | – |
| Q2 2018 | $29,000 | -85.4% | 12,399 | -80.1% | 0.00% | – |
| Q1 2018 | $198,000 | -7.5% | 62,211 | +19.4% | 0.00% | – |
| Q4 2017 | $214,000 | +72.6% | 52,106 | +89.8% | 0.00% | – |
| Q3 2017 | $124,000 | -78.2% | 27,453 | -83.9% | 0.00% | – |
| Q2 2017 | $568,000 | -89.4% | 170,439 | -70.8% | 0.00% | -100.0% |
| Q1 2017 | $5,367,000 | +1521.5% | 582,730 | +1259.2% | 0.00% | – |
| Q4 2016 | $331,000 | -8.1% | 42,872 | +36.2% | 0.00% | – |
| Q3 2016 | $360,000 | +7.8% | 31,486 | +16.2% | 0.00% | – |
| Q2 2016 | $334,000 | -78.9% | 27,092 | -82.7% | 0.00% | – |
| Q1 2016 | $1,584,000 | -37.9% | 156,611 | +38.4% | 0.00% | – |
| Q4 2015 | $2,549,000 | +48.7% | 113,137 | +9.5% | 0.00% | – |
| Q3 2015 | $1,714,000 | +261.6% | 103,297 | +633.9% | 0.00% | – |
| Q1 2014 | $474,000 | -40.7% | 14,076 | -48.0% | 0.00% | – |
| Q4 2013 | $799,000 | +287.9% | 27,054 | +101.0% | 0.00% | – |
| Q3 2013 | $206,000 | – | 13,459 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |